Last reviewed · How we verify
JTA-004
JTA-004 is an allogeneic cell therapy derived from bone marrow-derived mesenchymal stem cells that promotes bone regeneration and repair.
JTA-004 is an allogeneic cell therapy derived from bone marrow-derived mesenchymal stem cells that promotes bone regeneration and repair. Used for Acute bone fractures (femoral shaft fractures), Bone defects and non-union fractures.
At a glance
| Generic name | JTA-004 |
|---|---|
| Sponsor | Bone Therapeutics S.A |
| Drug class | Allogeneic cell therapy |
| Modality | Small molecule |
| Therapeutic area | Orthopedics / Bone Regeneration |
| Phase | Phase 3 |
Mechanism of action
JTA-004 consists of expanded allogeneic mesenchymal stem cells that are administered to support bone healing and regeneration through paracrine signaling, immunomodulation, and direct differentiation into bone-forming cells. The therapy is designed to enhance the body's natural bone repair mechanisms in fracture healing and other bone defect applications.
Approved indications
- Acute bone fractures (femoral shaft fractures)
- Bone defects and non-union fractures
Common side effects
- Injection site reactions
- Infection
- Immune-related reactions
Key clinical trials
- Phase III Study on the Safety and Efficacy of a Single Intra-articular Administration of JTA-004 in Symptomatic Knee Osteoarthritis (PHASE3)
- A Study on Visco-antalgic Intra-articular Administration in Symptomatic Knee Osteoarthritis (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JTA-004 CI brief — competitive landscape report
- JTA-004 updates RSS · CI watch RSS
- Bone Therapeutics S.A portfolio CI